Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Patients with autism spectrum disorders display reproducible functional connectivity alterations.

Holiga Š, Hipp JF, Chatham CH, Garces P, Spooren W, D'Ardhuy XL, Bertolino A, Bouquet C, Buitelaar JK, Bours C, Rausch A, Oldehinkel M, Bouvard M, Amestoy A, Caralp M, Gueguen S, Ly-Le Moal M, Houenou J, Beckmann CF, Loth E, Murphy D, Charman T, Tillmann J, Laidi C, Delorme R, Beggiato A, Gaman A, Scheid I, Leboyer M, d'Albis MA, Sevigny J, Czech C, Bolognani F, Honey GD, Dukart J.

Sci Transl Med. 2019 Feb 27;11(481). pii: eaat9223. doi: 10.1126/scitranslmed.aat9223.

PMID:
30814340
2.

Investigating the factors underlying adaptive functioning in autism in the EU-AIMS Longitudinal European Autism Project.

Tillmann J, San José Cáceres A, Chatham CH, Crawley D, Holt R, Oakley B, Banaschewski T, Baron-Cohen S, Bölte S, Buitelaar JK, Durston S, Ham L, Loth E, Simonoff E, Spooren W, Murphy DG, Charman T; EU-AIMS LEAP group.

Autism Res. 2019 Apr;12(4):645-657. doi: 10.1002/aur.2081. Epub 2019 Feb 11.

3.

Altered Connectivity Between Cerebellum, Visual, and Sensory-Motor Networks in Autism Spectrum Disorder: Results from the EU-AIMS Longitudinal European Autism Project.

Oldehinkel M, Mennes M, Marquand A, Charman T, Tillmann J, Ecker C, Dell'Acqua F, Brandeis D, Banaschewski T, Baumeister S, Moessnang C, Baron-Cohen S, Holt R, Bölte S, Durston S, Kundu P, Lombardo MV, Spooren W, Loth E, Murphy DGM, Beckmann CF, Buitelaar JK; EU-AIMS LEAP group.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Mar;4(3):260-270. doi: 10.1016/j.bpsc.2018.11.010. Epub 2018 Dec 5.

PMID:
30711508
4.

Glutamate and GABA in autism spectrum disorder-a translational magnetic resonance spectroscopy study in man and rodent models.

Horder J, Petrinovic MM, Mendez MA, Bruns A, Takumi T, Spooren W, Barker GJ, Künnecke B, Murphy DG.

Transl Psychiatry. 2018 May 25;8(1):106. doi: 10.1038/s41398-018-0155-1.

5.

EU-AIMS Longitudinal European Autism Project (LEAP): the autism twin cohort.

Isaksson J, Tammimies K, Neufeld J, Cauvet É, Lundin K, Buitelaar JK, Loth E, Murphy DGM, Spooren W, Bölte S; EU-AIMS LEAP group.

Mol Autism. 2018 Apr 13;9:26. doi: 10.1186/s13229-018-0212-x. eCollection 2018.

6.

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Berry-Kravis EM, Lindemann L, Jønch AE, Apostol G, Bear MF, Carpenter RL, Crawley JN, Curie A, Des Portes V, Hossain F, Gasparini F, Gomez-Mancilla B, Hessl D, Loth E, Scharf SH, Wang PP, Von Raison F, Hagerman R, Spooren W, Jacquemont S.

Nat Rev Drug Discov. 2018 Apr;17(4):280-299. doi: 10.1038/nrd.2017.221. Epub 2017 Dec 8. Review.

PMID:
29217836
7.

Comprehensive analysis of two Shank3 and the Cacna1c mouse models of autism spectrum disorder.

Kabitzke PA, Brunner D, He D, Fazio PA, Cox K, Sutphen J, Thiede L, Sabath E, Hanania T, Alexandrov V, Rasmusson R, Spooren W, Ghosh A, Feliciano P, Biemans B, Benedetti M, Clayton AL.

Genes Brain Behav. 2018 Jan;17(1):4-22. doi: 10.1111/gbb.12405. Epub 2017 Sep 5.

PMID:
28753255
8.

The EU-AIMS Longitudinal European Autism Project (LEAP): clinical characterisation.

Charman T, Loth E, Tillmann J, Crawley D, Wooldridge C, Goyard D, Ahmad J, Auyeung B, Ambrosino S, Banaschewski T, Baron-Cohen S, Baumeister S, Beckmann C, Bölte S, Bourgeron T, Bours C, Brammer M, Brandeis D, Brogna C, de Bruijn Y, Chakrabarti B, Cornelissen I, Acqua FD, Dumas G, Durston S, Ecker C, Faulkner J, Frouin V, Garcés P, Ham L, Hayward H, Hipp J, Holt RJ, Isaksson J, Johnson MH, Jones EJH, Kundu P, Lai MC, D'ardhuy XL, Lombardo MV, Lythgoe DJ, Mandl R, Mason L, Meyer-Lindenberg A, Moessnang C, Mueller N, O'Dwyer L, Oldehinkel M, Oranje B, Pandina G, Persico AM, Ruggeri B, Ruigrok ANV, Sabet J, Sacco R, Cáceres ASJ, Simonoff E, Toro R, Tost H, Waldman J, Williams SCR, Zwiers MP, Spooren W, Murphy DGM, Buitelaar JK.

Mol Autism. 2017 Jun 23;8:27. doi: 10.1186/s13229-017-0145-9. eCollection 2017.

9.

The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders.

Loth E, Charman T, Mason L, Tillmann J, Jones EJH, Wooldridge C, Ahmad J, Auyeung B, Brogna C, Ambrosino S, Banaschewski T, Baron-Cohen S, Baumeister S, Beckmann C, Brammer M, Brandeis D, Bölte S, Bourgeron T, Bours C, de Bruijn Y, Chakrabarti B, Crawley D, Cornelissen I, Acqua FD, Dumas G, Durston S, Ecker C, Faulkner J, Frouin V, Garces P, Goyard D, Hayward H, Ham LM, Hipp J, Holt RJ, Johnson MH, Isaksson J, Kundu P, Lai MC, D'ardhuy XL, Lombardo MV, Lythgoe DJ, Mandl R, Meyer-Lindenberg A, Moessnang C, Mueller N, O'Dwyer L, Oldehinkel M, Oranje B, Pandina G, Persico AM, Ruigrok ANV, Ruggeri B, Sabet J, Sacco R, Cáceres ASJ, Simonoff E, Toro R, Tost H, Waldman J, Williams SCR, Zwiers MP, Spooren W, Murphy DGM, Buitelaar JK.

Mol Autism. 2017 Jun 23;8:24. doi: 10.1186/s13229-017-0146-8. eCollection 2017.

10.

Neuroimaging, Genetics, and Clinical Data Sharing in Python Using the CubicWeb Framework.

Grigis A, Goyard D, Cherbonnier R, Gareau T, Papadopoulos Orfanos D, Chauvat N, Di Mascio A, Schumann G, Spooren W, Murphy D, Frouin V.

Front Neuroinform. 2017 Mar 16;11:18. doi: 10.3389/fninf.2017.00018. eCollection 2017.

11.

Defining Precision Medicine Approaches to Autism Spectrum Disorders: Concepts and Challenges.

Loth E, Murphy DG, Spooren W.

Front Psychiatry. 2016 Nov 29;7:188. eCollection 2016.

12.

Identification and validation of biomarkers for autism spectrum disorders.

Loth E, Spooren W, Ham LM, Isaac MB, Auriche-Benichou C, Banaschewski T, Baron-Cohen S, Broich K, Bölte S, Bourgeron T, Charman T, Collier D, de Andres-Trelles F, Durston S, Ecker C, Elferink A, Haberkamp M, Hemmings R, Johnson MH, Jones EJ, Khwaja OS, Lenton S, Mason L, Mantua V, Meyer-Lindenberg A, Lombardo MV, O'Dwyer L, Okamoto K, Pandina GJ, Pani L, Persico AM, Simonoff E, Tauscher-Wisniewski S, Llinares-Garcia J, Vamvakas S, Williams S, Buitelaar JK, Murphy DG.

Nat Rev Drug Discov. 2016 Jan;15(1):70-3. doi: 10.1038/nrd.2015.7. No abstract available.

PMID:
26718285
13.

New treatment targets for autism spectrum disorders: EU-AIMS.

Loth E, Spooren W, Murphy DG; EU-AIMS consortium.

Lancet Psychiatry. 2014 Nov;1(6):413-5. doi: 10.1016/S2215-0366(14)00004-2. Epub 2014 Nov 5. No abstract available.

PMID:
26361185
14.

Comprehensive Analysis of the 16p11.2 Deletion and Null Cntnap2 Mouse Models of Autism Spectrum Disorder.

Brunner D, Kabitzke P, He D, Cox K, Thiede L, Hanania T, Sabath E, Alexandrov V, Saxe M, Peles E, Mills A, Spooren W, Ghosh A, Feliciano P, Benedetti M, Luo Clayton A, Biemans B.

PLoS One. 2015 Aug 14;10(8):e0134572. doi: 10.1371/journal.pone.0134572. eCollection 2015.

15.

Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.

Lindemann L, Porter RH, Scharf SH, Kuennecke B, Bruns A, von Kienlin M, Harrison AC, Paehler A, Funk C, Gloge A, Schneider M, Parrott NJ, Polonchuk L, Niederhauser U, Morairty SR, Kilduff TS, Vieira E, Kolczewski S, Wichmann J, Hartung T, Honer M, Borroni E, Moreau JL, Prinssen E, Spooren W, Wettstein JG, Jaeschke G.

J Pharmacol Exp Ther. 2015 Apr;353(1):213-33. doi: 10.1124/jpet.114.222463. Epub 2015 Feb 9.

PMID:
25665805
16.

Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.

Jaeschke G, Kolczewski S, Spooren W, Vieira E, Bitter-Stoll N, Boissin P, Borroni E, Büttelmann B, Ceccarelli S, Clemann N, David B, Funk C, Guba W, Harrison A, Hartung T, Honer M, Huwyler J, Kuratli M, Niederhauser U, Pähler A, Peters JU, Petersen A, Prinssen E, Ricci A, Rueher D, Rueher M, Schneider M, Spurr P, Stoll T, Tännler D, Wichmann J, Porter RH, Wettstein JG, Lindemann L.

J Med Chem. 2015 Feb 12;58(3):1358-71. doi: 10.1021/jm501642c. Epub 2015 Feb 2.

PMID:
25565255
17.

European clinical network: autism spectrum disorder assessments and patient characterisation.

Ashwood KL, Buitelaar J, Murphy D, Spooren W, Charman T.

Eur Child Adolesc Psychiatry. 2015 Aug;24(8):985-95. doi: 10.1007/s00787-014-0648-2. Epub 2014 Dec 4.

PMID:
25471824
18.

Public-private partnership: a new engine for translational research in neurosciences.

Murphy DG, Goldman M, Loth E, Spooren W.

Neuron. 2014 Nov 5;84(3):533-6. doi: 10.1016/j.neuron.2014.10.006. Epub 2014 Nov 5.

19.

Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterization.

Malherbe P, Knoflach F, Marcuz A, Bohnert C, Weber M, Knust H, Ratni H, Spooren W, Ballard TM, Bissantz C.

Neuropharmacology. 2014 Nov;86:259-72. doi: 10.1016/j.neuropharm.2014.07.017. Epub 2014 Aug 5.

PMID:
25107588
20.

Alexander Rudolf Cools (1942-2013).

Ellenbroek BA, Homberg J, Verheij M, Spooren W, van den Bos R, Martens G.

Psychopharmacology (Berl). 2014 Jun;231(11):2219-22. doi: 10.1007/s00213-014-3583-5. Epub 2014 Apr 26. No abstract available.

PMID:
24770629
21.

Autism spectrum disorders--an emerging area in psychopharmacology.

Steckler T, Spooren W, Murphy D.

Psychopharmacology (Berl). 2014 Mar;231(6):977-8. doi: 10.1007/s00213-014-3460-2. No abstract available.

PMID:
24481571
22.

Using genetic findings in autism for the development of new pharmaceutical compounds.

Vorstman JA, Spooren W, Persico AM, Collier DA, Aigner S, Jagasia R, Glennon JC, Buitelaar JK.

Psychopharmacology (Berl). 2014 Mar;231(6):1063-78. doi: 10.1007/s00213-013-3334-z. Epub 2013 Nov 30. Review.

PMID:
24292384
23.

Developing new pharmacotherapies for autism.

Ecker C, Spooren W, Murphy D.

J Intern Med. 2013 Oct;274(4):308-20. doi: 10.1111/joim.12113. Epub 2013 Aug 10. Review.

24.

EU-AIMS: a boost to autism research.

Murphy D, Spooren W.

Nat Rev Drug Discov. 2012 Nov;11(11):815-6. doi: 10.1038/nrd3881.

PMID:
23123927
25.

Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders.

Spooren W, Lindemann L, Ghosh A, Santarelli L.

Trends Pharmacol Sci. 2012 Dec;33(12):669-84. doi: 10.1016/j.tips.2012.09.004. Epub 2012 Oct 18. Review.

PMID:
23084458
26.

Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism.

Baudouin SJ, Gaudias J, Gerharz S, Hatstatt L, Zhou K, Punnakkal P, Tanaka KF, Spooren W, Hen R, De Zeeuw CI, Vogt K, Scheiffele P.

Science. 2012 Oct 5;338(6103):128-32. doi: 10.1126/science.1224159. Epub 2012 Sep 13.

27.

Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity.

Saenger S, Holtmann B, Nilges MR, Schroeder S, Hoeflich A, Kletzl H, Spooren W, Ostrowitzki S, Hanania T, Sendtner M, Metzger F.

Amyotroph Lateral Scler. 2012 Sep;13(5):418-29. doi: 10.3109/17482968.2012.679944. Epub 2012 Aug 7.

PMID:
22871074
28.

Translational approaches to the biology of Autism: false dawn or a new era?

Ecker C, Spooren W, Murphy DG.

Mol Psychiatry. 2013 Apr;18(4):435-42. doi: 10.1038/mp.2012.102. Epub 2012 Jul 17. Review.

29.

Differential effects of diazepam and MPEP on habituation and neuro-behavioural processes in inbred mice.

Salomons AR, Pinzon NE, Boleij H, Kirchhoff S, Arndt SS, Nordquist RE, Lindemann L, Jaeschke G, Spooren W, Ohl F.

Behav Brain Funct. 2012 Jun 11;8:30. doi: 10.1186/1744-9081-8-30.

30.

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L.

Neuron. 2012 Apr 12;74(1):49-56. doi: 10.1016/j.neuron.2012.03.009.

31.

Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair.

Goeldner C, Spooren W, Wichmann J, Prinssen EP.

Psychopharmacology (Berl). 2012 Jul;222(2):203-14. doi: 10.1007/s00213-012-2636-x. Epub 2012 Jan 18.

PMID:
22249359
32.

PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disorders.

Saenger S, Goeldner C, Frey JR, Ozmen L, Ostrowitzki S, Spooren W, Ballard TM, Prinssen E, Borroni E, Metzger F.

Growth Horm IGF Res. 2011 Oct;21(5):292-303. doi: 10.1016/j.ghir.2011.07.006. Epub 2011 Aug 23.

PMID:
21865068
33.

CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.

Lindemann L, Jaeschke G, Michalon A, Vieira E, Honer M, Spooren W, Porter R, Hartung T, Kolczewski S, Büttelmann B, Flament C, Diener C, Fischer C, Gatti S, Prinssen EP, Parrott N, Hoffmann G, Wettstein JG.

J Pharmacol Exp Ther. 2011 Nov;339(2):474-86. doi: 10.1124/jpet.111.185660. Epub 2011 Aug 17.

PMID:
21849627
34.

Contingent negative variation as a dopaminergic biomarker: evidence from dose-related effects of methylphenidate.

Linssen AM, Vuurman EF, Sambeth A, Nave S, Spooren W, Vargas G, Santarelli L, Riedel WJ.

Psychopharmacology (Berl). 2011 Dec;218(3):533-42. doi: 10.1007/s00213-011-2345-x. Epub 2011 May 20.

35.

Metabotropic glutamate receptors: their therapeutic potential in anxiety.

Spooren W, Lesage A, Lavreysen H, Gasparini F, Steckler T.

Curr Top Behav Neurosci. 2010;2:391-413. Review.

PMID:
21309118
36.

Dissociable roles of mGlu5 and dopamine receptors in the rewarding and sensitizing properties of morphine and cocaine.

Veeneman MM, Boleij H, Broekhoven MH, Snoeren EM, Guitart Masip M, Cousijn J, Spooren W, Vanderschuren LJ.

Psychopharmacology (Berl). 2011 Apr;214(4):863-76. doi: 10.1007/s00213-010-2095-1. Epub 2010 Dec 1.

37.

Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.

Malherbe P, Knoflach F, Hernandez MC, Hoffmann T, Schnider P, Porter RH, Wettstein JG, Ballard TM, Spooren W, Steward L.

Br J Pharmacol. 2011 Feb;162(4):929-46. doi: 10.1111/j.1476-5381.2010.01096.x.

38.

Rational design of novel pyrrolidine derivatives as orally active neurokinin-3 receptor antagonists.

Ratni H, Ballard TM, Bissantz C, Hoffmann T, Jablonski P, Knoflach F, Knust H, Malherbe P, Nettekoven M, Patiny-Adam A, Riemer C, Schmitt M, Spooren W.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6735-8. doi: 10.1016/j.bmcl.2010.08.138. Epub 2010 Sep 17.

PMID:
20850972
39.

Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands.

Peters JU, Hoffmann T, Schnider P, Stadler H, Koblet A, Alker A, Poli SM, Ballard TM, Spooren W, Steward L, Sleight AJ.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3405-8. doi: 10.1016/j.bmcl.2010.04.008. Epub 2010 Apr 9.

PMID:
20430616
40.

Pharmacological characterization of senktide-induced tail whips.

Nordquist RE, Ballard TM, Algeyer B, Pauly-Evers M, Ozmen L, Spooren W.

Neuropharmacology. 2010 Jan;58(1):259-67. doi: 10.1016/j.neuropharm.2009.04.018. Epub 2009 Jun 21.

PMID:
19540857
41.

The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.

Nordquist RE, Durkin S, Jacquet A, Spooren W.

Eur J Pharmacol. 2008 Dec 14;600(1-3):87-92. doi: 10.1016/j.ejphar.2008.10.011. Epub 2008 Oct 10.

PMID:
18930726
42.

mGluR5 antagonists: discovery, characterization and drug development.

Gasparini F, Bilbe G, Gomez-Mancilla B, Spooren W.

Curr Opin Drug Discov Devel. 2008 Sep;11(5):655-65. Review.

PMID:
18729017
43.

Characterization of behavioral response to amphetamine, tyrosine hydroxylase levels, and dopamine receptor levels in neurokinin 3 receptor knockout mice.

Nordquist RE, Savignac H, Pauly-Evers M, Walker G, Knoflach F, Borroni E, Glaentzlin P, Bohrmann B, Messer J, Ozmen L, Albientz A, Spooren W.

Behav Pharmacol. 2008 Sep;19(5-6):518-29. doi: 10.1097/FBP.0b013e32830cd7f5.

PMID:
18690106
44.

Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors.

Malherbe P, Masciadri R, Norcross RD, Knoflach F, Kratzeisen C, Zenner MT, Kolb Y, Marcuz A, Huwyler J, Nakagawa T, Porter RH, Thomas AW, Wettstein JG, Sleight AJ, Spooren W, Prinssen EP.

Br J Pharmacol. 2008 Jun;154(4):797-811. doi: 10.1038/bjp.2008.135. Epub 2008 Apr 21.

45.

Cognitive performance in neurokinin 3 receptor knockout mice.

Nordquist RE, Delenclos M, Ballard TM, Savignac H, Pauly-Evers M, Ozmen L, Spooren W.

Psychopharmacology (Berl). 2008 Jun;198(2):211-20. doi: 10.1007/s00213-008-1119-6. Epub 2008 Mar 20.

PMID:
18351324
46.

Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety.

Nordquist RE, Steckler T, Wettstein JG, Mackie C, Spooren W.

Psychopharmacology (Berl). 2008 Aug;199(3):389-402. doi: 10.1007/s00213-008-1096-9. Epub 2008 Mar 6. Review.

PMID:
18322676
47.

Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains.

Malherbe P, Bissantz C, Marcuz A, Kratzeisen C, Zenner MT, Wettstein JG, Ratni H, Riemer C, Spooren W.

Mol Pharmacol. 2008 Jun;73(6):1736-50. doi: 10.1124/mol.107.042754. Epub 2008 Feb 28.

PMID:
18308898
48.

Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats.

Nordquist RE, Risterucci C, Moreau JL, von Kienlin M, Künnecke B, Maco M, Freichel C, Riemer C, Spooren W.

Neuropharmacology. 2008 Feb;54(2):405-16. Epub 2007 Oct 26.

PMID:
18054053
49.

Metabolite identification via LC-SPE-NMR-MS of the in vitro biooxidation products of a lead mGlu5 allosteric antagonist and impact on the improvement of metabolic stability in the series.

Ceccarelli SM, Schlotterbeck G, Boissin P, Binder M, Buettelmann B, Hanlon S, Jaeschke G, Kolczewski S, Kupfer E, Peters JU, Porter RH, Prinssen EP, Rueher M, Ruf I, Spooren W, Stämpfli A, Vieira E.

ChemMedChem. 2008 Jan;3(1):136-44.

PMID:
17994660
50.

Allosteric modulators for mGlu receptors.

Gasparini F, Spooren W.

Curr Neuropharmacol. 2007 Sep;5(3):187-94. doi: 10.2174/157015907781695900.

Supplemental Content

Loading ...
Support Center